Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas

International Journal of Dermatology

Volumn 50, Issue 9, 2011, Pages 1153-1161

  Kim, Kyu Han ^a,b   Kono, Takeshi ^a,b  

^a Seoul National University Hospital   (South Korea)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; ASIA; ATOPIC DERMATITIS; CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX; CHINA; CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; COMPARATIVE STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA AREA SEVERITY INDEX; EUROPE; HEAT SENSATION; HUMAN; INCIDENCE; INDONESIA; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALAYSIA; MULTICENTER STUDY; OINTMENT; OUTCOME ASSESSMENT; PAPULE; PATIENT'S ASSESSMENT OF ITCH; PEDIATRICS; PERCENT BODY SURFACE AREA; PHILIPPINES; PHYSICIAN'S GLOBAL EVALUATION OF CLINICAL RESPONSE; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGAPORE; SKIN BURNING SENSATION; SKIN INFECTION; TAIWAN; THAILAND; UNITED STATES;

ADMINISTRATION, TOPICAL; ADULT; ASIA, SOUTHEASTERN; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; FAR EAST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 80051868457     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04881.x     Document Type: Article

References (34)

1. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-S72.
2. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999; 41: 72-77.
3. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment vs betamethasone valerate ointment in atopic dermatitis (trunk/extremities) [in Japanese]. Nishinihon J Derm 1997; 59: 870-879.
4. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment vs alclometasone dipropionate ointment in atopic dermatitis (face and neck) [in Japanese]. Acta Derm (Kyoto) 1997; 92: 277-288.
5. Otsuki M, Nakagawa H, Kawashima M, et al. Efficacy and safety of FK506 (tacrolimus) ointment in children with atopic dermatitis: phase III double-blinded comparison with vehicle ointment. J Clin Ther Med 2003; 19: 569-595.
6. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-S38.
7. Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39-S46.
8. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44(1 Suppl): S47-S57.
9. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-555.
10. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
11. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: S186-S194.
12. Koo JY, Fleischer AB, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53: S195-S205.
13. Fleischer AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-570.
14. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-699.
15. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68-71.
16. Lan CC, Huang CC, Chen YT, et al. Tacrolimus ointment for the treatment of atopic dermatitis: report of first clinical experience in Taiwan. Kaohsiung J Med Sci 2003; 19: 296-304.
17. Won CH, Seo PG, Park YM, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatolog Treat 2004; 15: 30-34.
18. Kim HO, Park CW, Lee CH, et al. Efficacy of 0.1% tacrolimus ointment in Korean patients with atopic dermatitis. Korean J Dermatol 2005; 43: 312-318.
19. Yeung CK, Ma KC, Chan HH. Efficacy and safety of tacrolimus ointment monotherapy in Chinese children with atopic dermatitis. Skinmed 2006; 5: 12-17.
20. Singalavanija S, Noppakun N, Limpongsanuruk W, et al. Efficacy and safety of tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis. J Med Assoc Thai 2006; 89: 1915-1922.
21. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44-47.
22. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13-14.
23. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
25. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949.
26. Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
27. Toyoda M, Nakagawa H. Antipruritic mechanism of tacrolimus ointment for atopic eczema: 2. the role of neuropeptide, substance P [poster]. 16th EADV Congress, 16-20 May 2007.Vienna, Austria.
28. Toyoda M. Antipruritic mechanism of tacrolimus ointment for atopic dermatitis: consideration of dermatoneuronal factors. Clin Dermatol 2003; 57: 45-50.
29. Tan J, Langley R. Safety and efficacy of tacrolimus ointment 0.1% (Protopic) in atopic dermatitis: a Canadian open-label multicenter study. J Cutan Med Surg 2004; 8: 213-219.
30. Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat 2005; 16: 149-153.
31. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006; 6: 270-274.
32. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007; 27: 1020-1028.
33. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115: 1249-1253.
34. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.